- Freenome is a biotechnology company focused on early cancer detection through innovative blood-based screening tests, utilizing a multiomics approach to enhance diagnostic accuracy.
- In December 2025, Freenome announced a business combination agreement with Perceptive Capital Solutions Corp, securing $240 million in funding to support its AI/ML-enabled multi-cancer detection platform.
- Freenome has established a partnership with Roche to develop and commercialize cancer screening tests outside the U.S., enhancing its global market reach and capabilities.
- Freenome's ideal buyers are healthcare providers and diagnostic labs seeking advanced cancer screening solutions that improve early detection rates and patient outcomes, particularly in high-risk populations.
Engineering is the largest group at 195 employees, accounting for about 46% of the company. Scientific and business operations are represented by Healthcare (48) and Business Management (45), while Marketing and Product (24) and Operations (23) support go‑to‑market and program execution. Core enabling functions include Information Technology (18), Finance and Administration (18), Human Resources (15), and Quality (10). An additional 29 employees are categorized as Other, indicating coverage of specialized or cross‑functional roles.
Freenome’s workforce is concentrated in San Francisco with 162 employees, while a sizable 183 employees fall under Other, signaling a broad distributed footprint. Additional Bay Area locations include South San Francisco (21), San Jose (13), San Bruno (7), and Pleasanton (5), with further presence in San Diego (14). The company also maintains teams in key biotech and tech hubs such as Boston (9), Seattle (6), and New York (5). Overall, the distribution points to a strong Bay Area presence complemented by remote and multi-city teams across the U.S.
